All In Biotech

Drug Trial Radar · NCT06467344

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jun 11, 2024

Primary completion

Aug 1, 2030

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Ascidian Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

Conditions

  • Stargardt Disease
  • Cone Rod Dystrophy
  • Juvenile Macular Degeneration
  • Stargardt Disease 1

Interventions

  • ACDN-01Drug

    ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of ACDN-01 as measured by the number and severity of adverse events and serious adverse events.Time frame: 12 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of San Francisco

    San Francisco, California

  • Vitreo Retinal Associates

    Gainesville, Florida

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Wilmer Eye Institute at John Hopkins

    Baltimore, Maryland

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Casey Eye Institute OHSU

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Retina Consultants of Texas

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.